PMID- 32095377
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2167-8359 (Print)
IS  - 2167-8359 (Electronic)
IS  - 2167-8359 (Linking)
VI  - 8
DP  - 2020
TI  - HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in 
      Eastern China.
PG  - e8602
LID - 10.7717/peerj.8602 [doi]
LID - e8602
AB  - OBJECTIVE: To investigate the frequency and prognostic role of the human 
      epidermal growth factor receptor 2 gene (HER2) and BRAF V600E gene mutation in 
      Chinese patients with colorectal cancer (CRC). METHODS: Clinicopathological and 
      survival information from 480 patients with stage I-III CRC were reviewed and 
      recorded. HER2 amplification was analyzed by immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH), BRAF V600E mutation was tested by IHC 
      and Sanger sequencing. The relationship between HER2 and BRAF V600E mutation 
      status and clinicopathological characteristics and outcomes were determined. 
      RESULTS: The amplification of HER2 and BRAF V600E mutation were identified in 27 
      of 480 (5.63%) and 19 of 480 (3.96%) CRC patients, respectively. HER2 
      amplification significantly correlated with greater bowel wall invasion (P = 
      0.041) and more advanced TNM stage (I vs. II vs. III; 0 vs 5.78% vs. 7.41%, P = 
      0.013). Patients suffering from tumors with poor differentiation had a higher 
      incidence rate of BRAF V600E mutation than those with moderate/well 
      differentiation (7.77% vs 2.92%, P = 0.04). HER2 amplification was an independent 
      prognostic factor for worse disease-free survival (DFS) (HR = 2.53, 95% CI: 
      1.21-5.30, P = 0.014). CONCLUSION: The prevalence of HER2 amplification and BRAF 
      V600E mutation in stage I-III CRC patients in Chinese was 6% and 4%, 
      respectively, and HER2 amplification appeared to be associated with a worse DFS. 
      More comprehensive molecular classification and survival analysis are needed to 
      validate our findings.
CI  - (c) 2020 Zhang et al.
FAU - Zhang, Xiangyan
AU  - Zhang X
AD  - Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Wu, Jie
AU  - Wu J
AD  - Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Wang, Lili
AU  - Wang L
AD  - Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Zhao, Han
AU  - Zhao H
AD  - Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Li, Hong
AU  - Li H
AUID- ORCID: 0000-0003-4176-9900
AD  - Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Duan, Yuhe
AU  - Duan Y
AD  - Department of Pediatrics, Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Li, Yujun
AU  - Li Y
AD  - Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Xu, Ping
AU  - Xu P
AD  - Department of Obstetrics, Laixi People's Hospital, Qingdao, China.
FAU - Ran, Wenwen
AU  - Ran W
AD  - Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Xing, Xiaoming
AU  - Xing X
AD  - Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20200212
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
PMC - PMC7023828
OTO - NOTNLM
OT  - BRAF mutation
OT  - Colorectal cancer
OT  - Human epidermal growth factor receptor 2 gene
OT  - Prognosis
COIS- The authors declare that they have no competing interests.
EDAT- 2020/02/26 06:00
MHDA- 2020/02/26 06:01
PMCR- 2020/02/12
CRDT- 2020/02/26 06:00
PHST- 2019/06/13 00:00 [received]
PHST- 2020/01/19 00:00 [accepted]
PHST- 2020/02/26 06:00 [entrez]
PHST- 2020/02/26 06:00 [pubmed]
PHST- 2020/02/26 06:01 [medline]
PHST- 2020/02/12 00:00 [pmc-release]
AID - 8602 [pii]
AID - 10.7717/peerj.8602 [doi]
PST - epublish
SO  - PeerJ. 2020 Feb 12;8:e8602. doi: 10.7717/peerj.8602. eCollection 2020.